Cloning and characterization of marmoset renin: Comparison with human renin

Journal of Cardiovascular Pharmacology

Volumn 34, Issue 6, 1999, Pages 893-897

  Valdenaire, Olivier ^a,b   Breu, Volker ^a   Giller, Thomas ^a   Bur, Daniel ^a   Fischli, Walter ^a,c  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b INSERM   (France)

^c ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

Angiotensin; Angiotensinogen; Marmoset; Renin; Renin inhibitor

Indexed keywords

ANGIOTENSIN; ANGIOTENSINOGEN; RENIN; RENIN INHIBITOR;

AMINO ACID SEQUENCE; ARTICLE; HUMAN; MARMOSET; MOLECULAR CLONING; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION;

AMINO ACID SEQUENCE; ANGIOTENSINOGEN; ANIMALS; CALLITHRIX; CLONING, MOLECULAR; ENZYME PRECURSORS; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; RECOMBINANT PROTEINS; RENIN; RENIN-ANGIOTENSIN SYSTEM; RNA;

EID: 0032733745     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199912000-00018     Document Type: Article

References (31)

1. Waeber B, Nussberger J, Brunner HR. The renin-angiotensin system: role in experimental and human hypertension. In: Birkenhager WH, Reid JL, eds. Hypertension. Amsterdam: Elsevier Science Publishing, 1986:489-519.
2. Peach MJ. Renin-angiotensin system: biochemistry and mechanism of action. Physiol Rev 1977;57:313-70.
3. Menard J, Campbell DJ, Azizi M, Gonzales MF. Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats. Circulation 1997;96:3072-8.
4. Dzau VJ, Re R. Tissue angiotensin system in cardiovascular medicine: a paradigm shift? Circulation 1994;89:493-8.
5. Vaughan DE, Pfeffer MA. ACE inhibitors and cardiovascular remodelling. Cardiovasc Res 1994;28:159-65.
6. Erdös EG. Angiotensin I converting enzyme and the changes in our concepts through the years. Hypertension 1990;16:363-70.
7. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 1990;66:883-90.
8. Wolny A, Clozel JP, Rein J, et al. Functional and biochemical analysis of Ang II-forming pathways in human heart. Circ Res 1997;80:219-27.
9. Miura S, Ideishi M, Sakai T, et al. Angiotensin II formation by an alternative pathway during exercise in humans. J Hypertens 1994; 12:1177-81.
10. Hatae T, Takimoto E, Murakami K, Fukamizu A. Comparative studies on the species-specific reactivity between renin and angiotensinogen. Mol Cell Biochem 1994;131:43-7.
11. Kleinert H. Renin inhibition. Cardiovasc Drugs Ther 1995;9:645-55.
12. Fischli W, Clozel JP, El Amrani K, et al. Ro 42-5892 is a potent orally active renin inhibitor in primates. Hypertension 1991;18:22-31.
13. Clozel JP, Fischli W. Cyclosporin-induced hypertension in marmoset: a new model of hypertension sensitive to ACE inhibition. J Cardiovasc Pharmacol 1989;14:77-81.
14. Clozel JP, Fischli W. Comparative effects of three potent renin inhibitors in primates. Hypertension 1993;22:9-17.
15. Gerber PR, Mueller K. MAB, a generally applicable molecular force field for structure modelling in medicinal chemistry. J Comput Aided Mol Des 1995;9:251-68.
16. Nussberger J, Fasanella d'Amore T, Porchet M, et al. Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers. J Cardiovasc Pharmacol 1987;9:39-44.
17. Menard J, Guyene TT, Corvol P, Pau B, Simon D, Ronucci R. Direct immunometric assay of active renin in human plasma. J Hypertens 1985;3(suppl 3):275-8.
18. Oefner C, Binggeli A, Breu V, et al. Renin inhibition by substituted piperidines: a novel paradigm for the inhibition of monomeric aspartyl proteases. Chem Biol 1999;6:127-31.
19. Sielecki AR, Hayakawa K, Fujinaga M, et al. Structure of recombinant human renin: a target for cardiovascular-active drugs, at 2.5 A resolution. Science 1989;243:1346-51.
20. Chu WN, Mercure C, Baxter JD, Reudelhuber TL. Molecular determinants of human prorenin processing. Hypertension 1992;20: 782-7.
21. Mercure C, Thibault G, Lussier-Cacan S, Davignon J, Schiffrin EL, Reudelhuber TL. Molecular analysis of human prorenin pro-segment variants in vitro and in vivo. J Biol Chem 1995;270: 16355-9.
22. Mathews S, Doebeli H, Pruschy M, et al. Recombinant human renin produced in different expression systems: biochemical properties and 3D structure. Protein Expr Purif 1996;7:81-91.
23. Derkx F, Van den Meiracker A, Fischli W, et al. Nonparallel effects of renin inhibitor treatment on PRA and Ang I and Ang II in hypertensive subjects. Am J Hypertens 1991;4:602-9.
24. Poulsen K, Joergensen J. An easy radioimmunological microassay of renin activity, concentration and substrate in human and animal plasma and tissues based on angiotensin I trapping by antibody. J Clin Endocrinol Metab 1974;39:816-25.
25. Jeunemaitre X, Ménard J, Nussberger J, Guyene TT, Brunner HR, Corvol P. Plasma angiotensins, renin and blood pressure during acute renin inhibition by CGP 38560 A in hypertensive patients. Am J Hypertens 1989;2:819-27.
26. Fischli W, Clozel JP, Breu V, et al. Ciprokiren (Ro 44-9375): a renin inhibitor with increasing effects on chronic treatment. Hypertension 1994;2:163-9.
27. Camenzind E, Nussberger J, Juillerat L, et al. Effect of the renin response during renin inhibition: oral Ro 42-5892 in normal humans. J Cardiovasc Pharmacol 1991;18:299-307.
28. Kobrin I, Viskoper RJ, Laszt A, Bock J, Weber C, Charlon V. Effects of an orally active renin inhibitor, Ro 42-5892, in patients with essential hypertension. Am J Hypertens 1993;6:349-56.
29. Rongen GA, Lenders JW, Kleinbloesem CH, et al. Efficacy and tolerability of the renin inhibitor Ro 42-5892 in patients with hypertension. Clin Pharmacol Ther 1993;54:567-77.
30. van Paassen P, de Zeeuw D, de Jong PE. Renal and systemic effects of the renin inhibitor remikiren in patients with essential hypertension. J Cardiovasc Pharmacol 1995;26:39-45.
31. Kiowski W, Beermann J, Rickenbacher P, et al. Angiotensinergic versus nonangiotensinergic hemodynamic effects of converting enzyme inhibition in patients with chronic heart failure: assessment by acute renin and converting enzyme inhibition. Circulation 1994;90:2748-6.